Hey! How can I help you today?

am a dermatologist resident. Make me a best note of azathioprine.Use attached file as main source. Also Add from Fitzpatrick,bolognia and Andrew’s .also add from other sources. give source below each . Lastly provide thorough viva questions and answers. At last provide rapid revision note as well.Also add thorough quiz question with answer side by.Also provide clinical pearls.Add clinical based question. Just give me text

Reading File

Running Command

cd /home/daytona/workspace/attachments/8eace59c-d3e3-4e4e-b215-5d99bb6c0fdb && p…

Finding Sources

Running Command

cd /home/daytona/workspace/attachments/8eace59c-d3e3-4e4e-b215-5d99bb6c0fdb && p…

Reading File

Finding Sources

Reading File

Finding Sources

Searching PubMed

azathioprine dermatology TPMT monitoring

Reading File

Searching PubMed

azathioprine skin disease efficacy safety

Reading File

Finding Sources

AZATHIOPRINE - COMPREHENSIVE DERMATOLOGY RESIDENT NOTE

1. INTRODUCTION AND OVERVIEW

Azathioprine (trade names: Imuran, Azasan, Azamun) is a synthetic analog of natural purine bases (adenine and guanine) used in RNA and DNA synthesis. It was first synthesized in 1959 from its parent compound 6-mercaptopurine (6-MP) by George Hitchings and Gertrude Elion at Burroughs Wellcome (work that earned them the Nobel Prize in Physiology or Medicine in 1988). It became the drug of choice for organ transplantation in the 1960s-70s. Its moderately potent immunosuppressive and anti-inflammatory properties, combined with a reasonable risk-benefit profile and low cost, have led to widespread off-label use in dermatology.

Sources: Attached PDF (Badalamenti & Kerdel); Fitzpatrick's Dermatology, Vol 1-2; Dermatology 2-Volume Set 5e (Bolognia); Andrews' Diseases of the Skin

2. PHARMACOLOGY

2A. Formulations Available

25 mg, 50 mg (scored), 75 mg, 100 mg tablets
100 mg/vial injectable formulation

Source: Attached PDF, Table 14-1

2B. Absorption and Pharmacokinetics

Oral bioavailability: 88% (absorbed through the GI tract)
Peak plasma levels: less than 2 hours after oral dose
Protein binding: approximately 30%
Half-life: approximately 5 hours
Does NOT cross the blood-brain barrier
Readily crosses the placenta
Excreted in breast milk and colostrum
Virtually completely metabolized; negligible unmetabolized azathioprine is excreted

Source: Attached PDF, Table 14-2; Fitzpatrick's Dermatology block 30

2C. Metabolism - THREE COMPETING PATHWAYS (Critical Concept)

After absorption, azathioprine is rapidly converted to 6-MP (mainly within erythrocytes). 6-MP then enters one of three competing metabolic pathways:

PATHWAY 1 - ANABOLIC (Active): Via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) --> 6-thioguanine monophosphate (6-TG) and other 6-TG metabolites (including di- and triphosphate forms) --> immunosuppression. This is the active pathway.

PATHWAY 2 - CATABOLIC (Inactive): Via thiopurine methyltransferase (TPMT) --> inactive metabolites. TPMT activity is genetically polymorphic (critical for dosing).

PATHWAY 3 - CATABOLIC (Inactive): Via xanthine oxidase (XO) --> inactive metabolites. Inhibited by allopurinol/febuxostat (key drug interaction).

Key concept: If either catabolic pathway is blocked (TPMT genetic deficiency or XO inhibition by allopurinol), more 6-MP is shunted into the HGPRT anabolic pathway, leading to excessive 6-TG accumulation, resulting in excessive immunosuppression, bone marrow toxicity, and myelosuppression.

Source: Attached PDF, Table 14-3; Fitzpatrick's block 30; Dermatology 5e (Bolognia) block 29

3. THIOPURINE METHYLTRANSFERASE (TPMT) POLYMORPHISM - THE CORNERSTONE OF SAFE AZA USE

3A. Population Distribution of TPMT Activity

High activity: approximately 90% of population (homozygous wild-type: TPMT *1/*1)
Intermediate activity: approximately 10% of population (heterozygous: TPMT *1/*x)
Low/absent activity: less than 1% (about 1 in 300 persons) (homozygous mutant: TPMT *x/*x)

3B. Clinical Significance

Low TPMT: markedly increased 6-TG accumulation --> catastrophic myelosuppression risk. DO NOT use azathioprine.
Intermediate TPMT: increased risk but manageable with dose reduction.
High TPMT: may be therapeutically under-dosed at standard doses; may need dose titration upward.

3C. TPMT Testing

Phenotypic test: measures TPMT enzyme activity in RBCs (preferred; correlates well with systemic activity)
Genotypic test: sequences TPMT alleles (less preferred due to ethnic diversity of mutations; does not capture all low-activity variants)
TPMT activity is INDUCIBLE and not a constant; may vary over time

Genotype interpretation guide:

TPMT *1/*1 = High activity (homozygous wild-type)
TPMT *1/*x = Intermediate activity (heterozygous)
TPMT *x/*x = Low activity (homozygous mutant)

Note: Ethnic variation at the TPMT locus means some mutations are unique to certain ethnic groups, making the genetic test imperfect as a universal screening tool. The functional enzyme assay remains the most practical test.

3D. NUDT15 Polymorphism (Newer Data)

Recent rheumatology data suggests NUDT15 genetic variants should also be tested alongside TPMT before starting azathioprine therapy. NUDT15 variants are particularly important in East Asian populations.

Source: Firestein & Kelley's Textbook of Rheumatology; Attached PDF

4. DOSING BASED ON TPMT ACTIVITY (Mayo Clinic Reference Values)

TPMT Level	Value (U/mL RBC)	Maximum Azathioprine Dose
High (Normal)	15.1 - 26.4	Up to 2.0 - 2.5 mg/kg/day
Intermediate	6.3 - 15.0	Up to 1.0 mg/kg/day
Low	Less than 6.3	DO NOT USE

Empiric dosing (if TPMT not tested): generally start at 50 mg/day, increase to maximum 2.5 mg/kg/day based on clinical efficacy and monitoring
Onset of action: active metabolite 6-TG slowly accumulates; maximal clinical immunosuppression reached at approximately 8-12 weeks
Renal insufficiency: if GFR less than 10 mL/min, reduce dose by 50%; if GFR 10-50 mL/min, reduce dose by 25%

Source: Attached PDF, Table 14-1, Box 14-4; Dermatology 5e (Bolognia) Table 130.6

5. MECHANISM OF ACTION

The active metabolite 6-thioguanine (6-TG) is a purine analog structurally similar to adenine and guanine, but with a thiol group replacing the amino or hydroxyl group. Mechanisms include:

Incorporation into DNA and RNA --> inhibits purine metabolism and cell division (primarily affects rapidly dividing cells)
Inhibits T-cell mediated immune function (especially cell-mediated immunity)
Inhibits B-cell antibody production (important for immunobullous diseases - pemphigus vulgaris, bullous pemphigoid)
Reduces the number of Langerhans cells in skin and impairs their antigen-presenting capacity
Anti-inflammatory effects via inhibition of antigen-presenting cell function

Note: Patients with Lesch-Nyhan syndrome (HGPRT deficiency) experience NO immunosuppression or adverse effects with azathioprine because the anabolic pathway to 6-TG is blocked.

Source: Attached PDF; Fitzpatrick's block 30; Dermatology 5e (Bolognia) block 29

6. INDICATIONS AND USES IN DERMATOLOGY

6A. FDA-Approved Indications (not dermatology-specific)

Organ transplantation (prevention of rejection)
Severe rheumatoid arthritis

6B. Off-Label Dermatologic Uses

IMMUNOBULLOUS DISEASES (most common dermatologic indication):

Bullous pemphigoid - corticosteroid-sparing; RCTs show efficacy as adjuvant to prednisone
Pemphigus vulgaris - corticosteroid-sparing agent; adjuvant RCT showed azathioprine was most effective adjuvant in PV
Cicatricial (mucous membrane) pemphigoid
Linear IgA bullous dermatosis

CONNECTIVE TISSUE DISEASES:

Systemic lupus erythematosus (especially lupus nephritis)
Discoid lupus erythematosus (especially extensive lesions with palmoplantar involvement)
Dermatomyositis/polymyositis (muscle and respiratory symptoms respond; skin improvement less consistent)
Relapsing polychondritis (especially eye involvement)

NEUTROPHILIC DERMATOSES:

Behcet's disease - two placebo-controlled RCTs showed decreased ocular abnormalities, oral/genital ulcers, and arthritis
Pyoderma gangrenosum (variable success)

VASCULITIS:

Leukocytoclastic vasculitis (impressive results, especially rheumatoid arthritis-related LCV)
Wegener's granulomatosis
Polyarteritis nodosa
Giant cell arteritis
Retinal vasculitis

DERMATITIS AND PAPULOSQUAMOUS:

Severe atopic dermatitis - provides less expensive alternative to cyclosporine; well-established
Severe contact dermatitis
Chronic actinic dermatitis - RCT terminated early due to rapid statistical significance
Lichen planus (oral and cutaneous) - erosive and generalized forms
Psoriasis (rarely; combination with infliximab reported)
Persistent light reaction
Polymorphous light eruption (severe cases only)
Pityriasis rubra pilaris

OTHER:

Sarcoidosis (pulmonary features respond; cutaneous less predictable)
Persistent erythema multiforme
Chronic graft-versus-host disease

Source: Attached PDF, Box 14-1; Fitzpatrick's block 30, lines 47-85; Dermatology 5e (Bologna); Goodman & Gilman's Pharmacological Basis of Therapeutics

7. CONTRAINDICATIONS

Absolute:

Pregnancy (FDA Category D - crosses placenta; teratogenic)
Hypersensitivity to azathioprine
Low TPMT enzyme activity
Active clinically significant infections

Relative:

Concurrent allopurinol or febuxostat use (reduce azathioprine dose by 75% if must co-prescribe)
Prior use of alkylating agents (theoretically increased malignancy risk)
Breastfeeding (found in breast milk and colostrum)

Source: Attached PDF, Box 14-1

8. GENERAL GUIDELINES FOR USE IN DERMATOLOGY (Box 14-2)

Disease should be serious (potentially life-threatening or severely debilitating)
Disease should be reversible or controllable
Disease is unresponsive to less risky therapies
Disease should have measurable clinical or laboratory markers of improvement
Risks and adverse effects carefully discussed with patient
Alternative therapies discussed
Patient should be compliant with laboratory monitoring requirements

Source: Attached PDF, Box 14-2

9. ADVERSE EFFECTS

9A. Myelosuppression

Most serious adverse effect
May be acute or chronic onset
Occurs due to excessive 6-TG accumulation, interfering with DNA/RNA synthesis in high-turnover cells (hematopoietic precursors)
Higher rates in patients with intermediate TPMT (OR 4.5 for myelotoxicity vs. normal TPMT group; 95% CI 1.37-14.99)
Thrombocytopenia is often the earliest sign
Generalized depression of all blood cell lines most common
Stop drug if: WBC less than 3500-4000/mm3, Hgb less than 10 g/dL, platelets less than 100,000/mm3

Source: Attached PDF; Fitzpatrick's block 30

9B. Gastrointestinal Effects (Most Common)

Nausea, vomiting, diarrhea (most common side effects; most common reason for discontinuation)
Typically present between days 1-10 of therapy
Management: reduce dose, divide daily dose, take with food, add antiemetics
Pancreatitis (rare; more common in Crohn's disease patients)
Elevated liver transaminases (uncommon but important)

Source: Attached PDF; Fitzpatrick's block 30; Dermatology 5e (Bologna)

9C. Hepatotoxicity

Mild transaminase/bilirubin/alkaline phosphatase elevations: not uncommon, may be transient
Toxic hepatitis (drug-induced hepatotoxicity): approximately 1% with RA treatment; usually reversible
Hepatic veno-occlusive disease (rare but serious)
Nodular regenerative hyperplasia (rare)
LFTs should be monitored throughout treatment regardless of TPMT status
Hepatotoxicity is NOT associated with TPMT polymorphisms (unlike hematologic toxicity)

Source: Attached PDF; Fitzpatrick's block 30

9D. Hypersensitivity Syndrome

Rare but potentially life-threatening
Typically develops 1-4 weeks after initiating therapy
Symptoms: fever, cardiovascular collapse, cutaneous eruptions, leukocytosis, GI discomfort, nausea to hepatotoxicity/pancreatitis, arthralgias, myalgias, rhabdomyolysis, headaches, renal insufficiency, respiratory involvement (cough to pneumonitis)
Cutaneous eruptions: macular erythema, maculopapular, vesiculopustular, purpuric/petechial lesions, erythema multiforme, urticaria, angioedema, erythema nodosum
More common in patients also receiving cyclosporine or methotrexate
Rechallenge is ABSOLUTELY CONTRAINDICATED (may cause life-threatening reaction)

Source: Attached PDF; Fitzpatrick's block 30

9E. Malignancy / Carcinogenesis

Lymphoproliferative malignancies: especially non-Hodgkin's B-cell lymphomas
Cutaneous squamous cell carcinoma (SCC): Azathioprine increases SCC risk by 56%
Mechanism for SCC: increased UVA absorption, increased reactive oxygen species, mutagenic DNA damage; reduced minimal erythema dose to UVA
Risk influenced by: ethnicity, duration of treatment, depth of immunosuppression, and most importantly the underlying disease state
For dermatologic indications alone: no convincing evidence of significantly increased lymphoma risk; 3 case reports of aggressive SCC in eczema/atopic dermatitis/chronic actinic dermatitis patients (head and neck, fair-skinned, with sun exposure)
Risk much higher in transplant patients and RA patients than in dermatology patients

Source: Attached PDF; Fitzpatrick's block 30

9F. Infection Risk

Increased risk, especially with higher doses or multiple immunosuppressants
Herpes simplex virus, varicella-zoster, human papillomavirus, scabies
True opportunistic infections uncommon at doses used for dermatologic indications (unlike transplant doses)

9G. Teratogenicity / Reproductive Effects

FDA Category D
Crosses placenta
Various congenital malformations reported
Temporarily depresses spermatogenesis in mice
Found in breast milk and colostrum - avoid in breastfeeding

9H. Vaccination Caution

Avoid live vaccines in immunosuppressed patients
Hepatitis B vaccine (killed virus) may have decreased immune response when given with azathioprine and corticosteroids

Source: Attached PDF; Fitzpatrick's block 30

10. DRUG INTERACTIONS

Interacting Drug	Mechanism	Clinical Effect	Management
Allopurinol / Febuxostat	Inhibits XO (catabolic pathway)	Massive increase in 6-TG; myelosuppression	Reduce azathioprine by 75%
ACE inhibitors (e.g., captopril)	Unknown	Severe leukopenia	Monitor CBC closely
Warfarin	Unclear	Azathioprine DECREASES anticoagulant effect	May need significant warfarin dose INCREASE
Sulfasalazine / Aminosalicylates	Inhibits TPMT activity	Potentiates azathioprine toxicity	Minimize or avoid
Methotrexate (folate antagonists)	Increases 6-MP metabolite plasma levels	Enhanced myelosuppression	Monitor CBC
Cyclosporine	Azathioprine may decrease cyclosporine levels	Reduced immunosuppression	Monitor levels
Non-depolarizing neuromuscular blockers (pancuronium)	Unknown	Decreased/reversed neuromuscular blockade	May need increased dose of blocker
Co-trimoxazole, penicillamine	Both myelosuppressive	Additive myelosuppression	Avoid combination

Most important: ALLOPURINOL - reduce azathioprine dose by 75% if concurrent use is mandatory.

Source: Attached PDF, Table 14-4; Fitzpatrick's block 30; Dermatology 5e (Bologna)

11. MONITORING GUIDELINES

11A. Baseline Assessment

CLINICAL:

Full history and physical exam
Discuss risk-benefit profile, adverse effects, alternative treatments
Discuss sun avoidance (SCC risk)
Discuss contraception/abstinence (women of childbearing potential)
Elicit history of prior alkylating agents, current allopurinol/febuxostat use

LABORATORY:

Pregnancy test (women of childbearing potential)
CBC with differential and platelet count
Comprehensive metabolic panel (LFTs, creatinine, BUN)
Urinalysis
Tuberculin skin test (PPD/IGRA) - strongly consider
TPMT enzyme activity assay (phenotype testing - preferred)

11B. Follow-up Monitoring

LABORATORY SCHEDULE:

Biweekly for first 2 months
Every 2-3 months thereafter
With any dose escalation

TESTS AT EACH FOLLOW-UP:

CBC with differential WBC count
Liver function tests (AST and/or ALT)

ANNUAL:

Complete physical examination with attention to:
- Lymphadenopathy (lymphoma detection)
- Skin examination for SCC
- Sun counseling reinforcement

Note: TPMT assay does NOT need to be repeated after baseline. However, more frequent CBC monitoring is recommended if baseline TPMT was not obtained.

Source: Attached PDF, Box 14-4; Fitzpatrick's block 30

11C. Thresholds for Drug Modification/Cessation

WBC less than 3500-4000/mm3
Hemoglobin less than 10 g/dL
Platelets less than 100,000/mm3
Significant hepatotoxicity (rising transaminases)
Any hypersensitivity syndrome features

12. SPECIAL POPULATIONS

Pregnancy: Category D - CONTRAINDICATED
Breastfeeding: CONTRAINDICATED (drug present in breast milk)
Renal impairment: GFR 10-50 mL/min = reduce by 25%; GFR less than 10 mL/min = reduce by 50%
Elderly: Use with caution due to increased infection risk and hematologic sensitivity
Prior alkylating agent use: Relative contraindication (theoretical additive malignancy risk)

13. PEARLS FROM FITZPATRICK'S DERMATOLOGY (8th Ed.)

In a randomized clinical trial of adjuvant immunosuppressants in pemphigus vulgaris, azathioprine was the most effective adjuvant
In Behcet's disease, azathioprine decreased ocular abnormalities (hypopyon, emergent blindness) and extraocular complications including oral/genital ulcers and arthritis
Chronic actinic dermatitis RCT with azathioprine was terminated early due to rapid statistical significance
Improvement in chronic actinic dermatitis appeared permanent after mean 11.5 months of treatment
In dermatomyositis/polymyositis, azathioprine shows efficacy in improving myositis in up to 75% of cases in combined studies and improved survival
Azathioprine is less effective for the skin component of dermatomyositis vs. muscle component

Source: Fitzpatrick's Dermatology, block 30

14. PEARLS FROM DERMATOLOGY 5E (BOLOGNA)

Azathioprine decreases the number of Langerhans cells in the skin and inhibits their ability to present antigens - this explains its utility in photodermatoses
Azathioprine should be reserved for serious, life-threatening, or recalcitrant dermatoses after other therapies have failed
The reduced minimal erythema dose to UVA is the mechanism by which azathioprine increases SCC risk
Ethnic variations at the TPMT locus exist; do not profile a specific ethnic group - use the functional enzyme assay

Source: Dermatology 5e (Bologna), block 29

15. PEARLS FROM ANDREWS' DISEASES OF THE SKIN

Azathioprine is considered a second-line systemic option across many inflammatory dermatoses
Used as corticosteroid-sparing agent in immunobullous diseases
For bullous pemphigoid, the European Academy of Dermatology and Venereology 2015 consensus recommends azathioprine as an adjuvant to corticosteroids for initial therapy

Source: Andrews' Diseases of the Skin, block 6

16. RECENT EVIDENCE (PubMed 2021-2026)

Systemic treatments for atopic dermatitis - systematic review and network meta-analysis (J Allergy Clin Immunol, 2023; PMID: 37678577): Azathioprine was included as a comparator in network meta-analyses for atopic dermatitis systemic treatments. Newer biologics (dupilumab, JAK inhibitors) demonstrate superior efficacy, but azathioprine remains a cost-effective option particularly in resource-limited settings.
JAAD Guidelines for management of atopic dermatitis in adults with phototherapy and systemic therapies (JAAD, 2024; PMID: 37943240): Practice guidelines acknowledge azathioprine as a traditional systemic option for moderate-to-severe atopic dermatitis.
Living Systematic Review update - Systemic Immunomodulatory Treatments for Atopic Dermatitis (JAMA Dermatol, 2024; PMID: 39018058): Azathioprine demonstrated efficacy vs. placebo but is now ranked below biologics in the evidence hierarchy for atopic dermatitis treatment.

Note: These recent systematic reviews confirm azathioprine remains a valid, evidence-based option for atopic dermatitis, particularly where biologics are unavailable or too costly, though biologics now represent the preferred systemic treatment when accessible.

CLINICAL PEARLS

TPMT TEST BEFORE PRESCRIBING - the single most important pre-treatment test. Use the phenotypic (enzyme activity) assay, NOT just the genotype, because TPMT is inducible and ethnic diversity means genotype misses many variants.
THE 75% RULE WITH ALLOPURINOL - if a patient is on allopurinol for gout and needs azathioprine, reduce the azathioprine dose by 75%. Consider switching to febuxostat (though febuxostat has a similar XO-inhibiting interaction!). Many clinicians prefer switching the gout drug entirely.
ONSET TAKES 8-12 WEEKS - azathioprine is not a quick-fix. 6-TG accumulates slowly. Patients must be counseled on patience and kept on corticosteroids as bridging therapy.
WARFARIN PARADOX - unlike most immunosuppressants, azathioprine DECREASES the anticoagulant effect of warfarin. Patients on warfarin may need significantly increased warfarin doses.
HYPERSENSITIVITY WITHIN 4 WEEKS - if fever, rash, GI upset, and cardiovascular instability occur in first 1-4 weeks, think azathioprine hypersensitivity syndrome. Stop immediately and NEVER rechallenge.
SCC AND SUN - azathioprine photosensitizes patients to UVA by reducing their minimal erythema dose. Strict photoprotection (SPF 50+, sun-protective clothing, sun avoidance) is mandatory. Annual skin checks.
THROMBOCYTOPENIA FIRST - in early myelosuppression, thrombocytopenia is often the first sign. Watch platelet trends carefully.
PANCREATITIS - rare but recognized. More specifically associated with Crohn's disease patients. If abdominal pain develops, check amylase/lipase.
PREGNANCY CAUTION - Category D. Despite this, azathioprine is actually used in pregnancy for SLE/IBD by some specialists (the risk-benefit is complex). For purely dermatologic indications, it should be stopped pre-conception.
LESCH-NYHAN TRICK - patients with Lesch-Nyhan syndrome (HGPRT deficiency) get NO immunosuppression from azathioprine because the anabolic pathway is blocked. This is a classic exam question.
LANGERHANS CELL REDUCTION - azathioprine uniquely reduces Langerhans cells in skin and impairs antigen presentation, which explains its specific utility in chronic actinic dermatitis and photodermatoses beyond its general immunosuppression.
SULFASALAZINE INTERACTION - sulfasalazine and aminosalicylates inhibit TPMT. If a patient is on mesalazine/sulfasalazine (e.g., IBD patient), TPMT activity may be falsely suppressed, leading to unexpected azathioprine toxicity.

VIVA QUESTIONS AND ANSWERS

Q1: What are the three metabolic pathways of azathioprine? Which pathway leads to active metabolites? A: (1) HGPRT pathway - anabolic, produces 6-TG (active metabolites); (2) TPMT pathway - catabolic, produces inactive metabolites; (3) Xanthine oxidase pathway - catabolic, produces inactive metabolites. Only the HGPRT pathway produces active immunosuppressive metabolites.

Q2: Why is azathioprine called a prodrug? A: Azathioprine itself is pharmacologically inactive. Upon absorption (mainly in erythrocytes), it is rapidly converted to 6-mercaptopurine (6-MP), which is then further metabolized to the active compound 6-thioguanine (6-TG) via HGPRT.

Q3: What is the significance of TPMT polymorphism in azathioprine therapy? A: TPMT is one of the two catabolic enzymes for 6-MP. Patients with low TPMT activity cannot adequately catabolize 6-MP through this pathway, shunting more substrate into the anabolic HGPRT pathway, leading to excessive 6-TG accumulation, causing severe/catastrophic myelosuppression. Hence TPMT phenotype testing is mandatory before starting azathioprine.

Q4: What is the dose of azathioprine based on TPMT levels? A: High TPMT (15.1-26.4 U/mL): up to 2.0-2.5 mg/kg/day. Intermediate TPMT (6.3-15 U/mL): up to 1.0 mg/kg/day. Low TPMT (less than 6.3 U/mL): DO NOT USE.

Q5: What is the most important drug interaction with azathioprine and what is the mechanism? A: Allopurinol (and febuxostat) - these inhibit xanthine oxidase, the second catabolic pathway for 6-MP. With XO blocked, more 6-MP is funneled into the anabolic HGPRT pathway, producing excessive 6-TG, leading to severe myelosuppression. If concurrent use is unavoidable, reduce azathioprine dose by 75%.

Q6: Why does azathioprine have no effect in Lesch-Nyhan syndrome? A: Lesch-Nyhan syndrome involves deficiency of HGPRT, the enzyme required to convert 6-MP into the active 6-TG metabolites. Without HGPRT activity, azathioprine cannot generate its active immunosuppressive metabolites, so the drug has no clinical effect.

Q7: What is the timeline of onset of action of azathioprine? A: Clinical immunosuppression begins gradually as 6-TG accumulates in tissues. Maximum clinical effect is typically reached at 8-12 weeks with traditional dosing. Patients should be bridged with corticosteroids until azathioprine takes effect.

Q8: What are the features of azathioprine hypersensitivity syndrome? A: Occurs 1-4 weeks after initiation. Features: fever, cardiovascular collapse (hypotension), cutaneous eruptions (morbilliform, urticaria, angioedema, EM, erythema nodosum, purpura), leukocytosis, GI symptoms, hepatotoxicity, pancreatitis, arthralgias, myalgias, rhabdomyolysis, renal insufficiency, pneumonitis. More common with concomitant cyclosporine or methotrexate. Rechallenge is absolutely contraindicated.

Q9: How does azathioprine increase the risk of squamous cell carcinoma? A: Azathioprine reduces the minimal erythema dose to UVA radiation. It causes increased UVA absorption and generates reactive oxygen species, leading to mutagenic DNA damage in keratinocytes. The resulting genomic instability is conducive to SCC development.

Q10: What is the monitoring schedule for azathioprine? A: Baseline: CBC, LFTs, CMP, urinalysis, pregnancy test, PPD/IGRA, TPMT activity. Follow-up: biweekly for first 2 months, then every 2-3 months. Annual full physical exam for SCC and lymphoma. TPMT does NOT need to be repeated.

Q11: What are the GI side effects of azathioprine and how do you manage them? A: Nausea, vomiting, diarrhea - most common side effects, typically in days 1-10. Management: reduce dose, divide dose, take with food, add antiemetics (metoclopramide, ondansetron).

Q12: Why does azathioprine decrease warfarin effect? A: Unlike most drugs, azathioprine DECREASES the anticoagulant effect of warfarin by an unclear mechanism. Patients on warfarin may require significantly higher warfarin doses when azathioprine is added.

Q13: What is the phenotypic vs genotypic test for TPMT and why is phenotype preferred? A: Phenotypic test measures actual TPMT enzyme activity in RBCs. Genotypic test sequences TPMT alleles looking for known mutations. Phenotype is preferred because: (1) TPMT is inducible (activity can change), (2) ethnic diversity means not all low-activity mutations are captured in current genotypic panels, (3) phenotype reflects actual functional activity.

Q14: Name five off-label dermatologic uses of azathioprine. A: (Any five from): Pemphigus vulgaris, bullous pemphigoid, cicatricial pemphigoid, atopic dermatitis, dermatomyositis, SLE/discoid lupus, Behcet's disease, pyoderma gangrenosum, leukocytoclastic vasculitis, chronic actinic dermatitis, lichen planus, polymorphous light eruption, psoriasis, relapsing polychondritis, sarcoidosis, erythema multiforme, GVHD.

Q15: What WBC count should prompt cessation of azathioprine? A: WBC less than 3500-4000/mm3, or hemoglobin less than 10 g/dL, or platelets less than 100,000/mm3. Temporary drug cessation should allow bone marrow recovery.

Q16: How is azathioprine different from 6-mercaptopurine? A: Azathioprine and 6-MP are equally potent when given parenterally, but azathioprine has superior oral bioavailability (88%), better GI absorption, and more predictable systemic levels, making it preferred for oral dermatologic use. Azathioprine is essentially a prodrug of 6-MP.

Q17: Which ethnic group has a particularly high prevalence of NUDT15 variants relevant to azathioprine toxicity? A: East Asian populations have a higher prevalence of NUDT15 variants (particularly NUDT15 R139C mutation), which predispose to azathioprine-induced myelosuppression. Testing for both TPMT and NUDT15 is recommended when prescribing azathioprine to East Asian patients.

Q18: What happens to azathioprine if the patient is on sulfasalazine? A: Sulfasalazine (and aminosalicylates like mesalamine) inhibit TPMT enzyme activity, effectively reducing the catabolic TPMT pathway. This shifts more 6-MP into the anabolic HGPRT pathway, increasing 6-TG levels and potentiating azathioprine toxicity (especially myelosuppression). TPMT levels may also be falsely low in these patients on functional assay.

CLINICAL-BASED QUESTIONS

CASE 1: A 45-year-old man with pemphigus vulgaris is started on azathioprine 2 mg/kg/day and prednisolone. At week 3, he develops fever (38.9°C), nausea, vomiting, a diffuse macular rash, and his BP drops to 85/50 mmHg. What is the diagnosis and management?

Answer: Azathioprine hypersensitivity syndrome. This is a life-threatening reaction. Management: (1) IMMEDIATELY stop azathioprine; (2) supportive IV fluids, vasopressors if needed for cardiovascular collapse; (3) do NOT rechallenge with azathioprine EVER; (4) maintain prednisolone for disease control; (5) consider switching to mycophenolate mofetil or cyclophosphamide as the steroid-sparing agent; (6) document the reaction clearly.

CASE 2: A 32-year-old woman with severe atopic dermatitis is to be started on azathioprine. Her TPMT level comes back at 8.5 U/mL. What dose do you prescribe?

Answer: TPMT of 8.5 U/mL falls in the intermediate range (6.3-15 U/mL). The maximum dose is 1.0 mg/kg/day. Start at 50 mg/day and titrate carefully while monitoring CBC biweekly. She is at higher risk of myelosuppression than a patient with normal TPMT. Counsel on signs of bone marrow suppression (bruising, bleeding, infections).

CASE 3: A 60-year-old male with gout (on allopurinol 300 mg/day) develops bullous pemphigoid. You want to start azathioprine as a steroid-sparing agent. How do you proceed?

Answer: Critical drug interaction. Options: (1) Preferred: switch allopurinol to a non-XO-inhibiting urate-lowering agent (e.g., probenecid - but note febuxostat ALSO inhibits XO, so avoid it too); OR (2) If allopurinol must be continued: reduce azathioprine dose by 75% (e.g., if planned dose was 2 mg/kg/day, give 0.5 mg/kg/day). Monitor CBC very closely. Mycophenolate mofetil is a safer alternative steroid-sparing agent in patients who cannot stop allopurinol.

CASE 4: A patient on azathioprine for chronic actinic dermatitis comes to clinic with a rapidly growing, ulcerated lesion on the dorsal hand. Biopsy shows well-differentiated SCC. How does azathioprine relate to this?

Answer: Azathioprine is associated with increased risk of cutaneous SCC. Mechanism: it reduces the minimal erythema dose to UVA, increases reactive oxygen species, causes mutagenic DNA damage. The risk is particularly high in fair-skinned patients with significant UV exposure. Management: (1) excise SCC with clear margins; (2) reassess risk-benefit of continuing azathioprine; (3) if continuing, implement strict photoprotection (SPF 50+, UPF clothing, sun avoidance); (4) quarterly skin checks; (5) consider switching to a less carcinogenic immunosuppressant (e.g., mycophenolate).

CASE 5: A 28-year-old woman on azathioprine for SLE develops easy bruising and her CBC shows platelets of 75,000/mm3. WBC is 4,200/mm3 and Hgb is 11.2 g/dL. TPMT was normal at baseline. What do you do?

Answer: Despite normal TPMT at baseline, azathioprine-induced myelosuppression has occurred (thrombocytopenia is often the first sign). The platelet count of 75,000 is below the threshold of 100,000/mm3 for safe continuation. Actions: (1) Temporarily stop azathioprine; (2) Monitor CBC closely; (3) Allow bone marrow recovery (usually occurs with drug cessation); (4) Once recovered, consider restarting at a lower dose with more frequent monitoring; (5) Check if any new drug interactions (e.g., has she started sulfasalazine, aminosalicylates, or any OTC product?); (6) Measure serial CBC and 6-TG levels if available; (7) Consider switching to mycophenolate mofetil if azathioprine is not tolerated.

CASE 6: A 55-year-old man with psoriasis and concurrent IBD on mesalamine asks about starting azathioprine. What specific concern do you have?

Answer: Mesalamine (an aminosalicylate) inhibits TPMT enzyme activity. This means: (1) the patient's TPMT functional assay may give a falsely low result due to mesalamine's TPMT-inhibiting effect; (2) even if TPMT appears normal, the effective TPMT activity during co-administration will be reduced, increasing the risk of 6-TG accumulation and myelosuppression. Management: stop mesalamine at least 2 weeks before measuring TPMT activity; reduce azathioprine dose and monitor CBC more frequently if both drugs are used together; consider alternative biologics for psoriasis in this complex patient.

RAPID REVISION NOTE - AZATHIOPRINE

DRUG: Azathioprine (Imuran, Azasan) | Prodrug of 6-MP | Synthesized 1959

METABOLISM: AZA --> 6-MP (in RBCs) --> Three competing pathways:

HGPRT --> 6-TG (ACTIVE - immunosuppression)
TPMT --> inactive (GENETIC polymorphism)
XO --> inactive (inhibited by ALLOPURINOL - 75% dose reduction)

TPMT LEVELS (Mayo):

Greater than 15.1: normal - use 2-2.5 mg/kg/day
6.3-15: intermediate - use 1 mg/kg/day
Less than 6.3: low - DO NOT USE

ONSET: 8-12 weeks (slow 6-TG accumulation)

TOP DERMATOLOGY USES: Pemphigus vulgaris, Bullous pemphigoid, Atopic dermatitis, Dermatomyositis, SLE, Behcet's, Chronic actinic dermatitis, LCV, Lichen planus

FDA APPROVED: Organ transplant + Rheumatoid arthritis only (all dermatology = OFF-LABEL)

KEY DRUG INTERACTION: Allopurinol/Febuxostat (XO inhibitors) --> reduce AZA by 75% Others: ACE inhibitors (leukopenia), Warfarin (decreased effect), Sulfasalazine (TPMT inhibition), Methotrexate (increased 6-MP levels)

ADVERSE EFFECTS (MNEMONIC: "MAGIC"):

Myelosuppression (WBC less than 3500, Plt less than 100k, Hgb less than 10 --> STOP)
Allergy/Hypersensitivity syndrome (1-4 weeks; NO rechallenge)
GI effects (most common; nausea/vomiting; take with food)
Infection (HSV, HPV, scabies)
Carcinogenesis (SCC 56% increased risk via UVA sensitization; NHL/B-cell lymphoma)

CONTRAINDICATIONS: Pregnancy (Cat D), Low TPMT, Hypersensitivity to AZA, Active significant infection

MONITORING:

BASELINE: TPMT, CBC, LFTs, CMP, pregnancy test, PPD
FOLLOW-UP: CBC + LFTs biweekly x 2 months, then every 2-3 months
ANNUAL: Full skin exam (SCC) + lymph node exam (lymphoma)

LESCH-NYHAN TRICK: HGPRT deficiency = NO AZA effect (can't make active 6-TG)

SCC MECHANISM: Reduces MED to UVA + reactive oxygen species --> mutagenic DNA damage

WARFARIN PARADOX: AZA decreases anticoagulant effect of warfarin

THOROUGH QUIZ - AZATHIOPRINE

QUESTION 1: Azathioprine is primarily a prodrug of which compound? A. 6-Thioguanine B. 6-Mercaptopurine C. Mercaptopurine ribonucleotide D. Thioguanine monophosphate

ANSWER: B. 6-Mercaptopurine. After absorption, azathioprine is rapidly converted to 6-MP mainly within erythrocytes. 6-MP is then further metabolized to 6-TG (the ultimate active metabolite) via HGPRT.

QUESTION 2: A patient with TPMT level of 4.2 U/mL is referred for azathioprine therapy for pemphigus vulgaris. The correct approach is: A. Start at 1 mg/kg/day with close monitoring B. Start at 0.5 mg/kg/day C. Do not use azathioprine D. Use 2 mg/kg/day with weekly CBC

ANSWER: C. Do not use azathioprine. A TPMT level of 4.2 U/mL is below 6.3 U/mL (low range). Low TPMT activity means catastrophic myelosuppression risk. Consider mycophenolate mofetil as an alternative steroid-sparing agent.

QUESTION 3: Allopurinol interacts with azathioprine by: A. Inhibiting TPMT leading to reduced 6-TG production B. Inhibiting xanthine oxidase leading to excess 6-TG accumulation C. Directly competing with azathioprine for HGPRT D. Enhancing renal clearance of azathioprine

ANSWER: B. Allopurinol inhibits xanthine oxidase (XO), one of two catabolic pathways for 6-MP. With XO blocked, more 6-MP is forced through the anabolic HGPRT pathway, producing excess 6-TG, leading to myelosuppression. Dose reduction of 75% required.

QUESTION 4: The mechanism by which azathioprine increases risk of squamous cell carcinoma includes: A. Direct mutagenesis of p53 gene B. Reduced minimal erythema dose to UVA and reactive oxygen species generation C. Immunosuppression allowing HPV to drive carcinogenesis only D. Increased UVB photosensitivity

ANSWER: B. Azathioprine reduces the minimal erythema dose to UVA (not UVB), increases reactive oxygen species, and causes mutagenic DNA damage conducive to SCC. One small case series confirmed reduced MED-UVA with azathioprine. It increases SCC risk by approximately 56%.

QUESTION 5: Which of the following is NOT a feature of azathioprine hypersensitivity syndrome? A. Cardiovascular collapse within 1-4 weeks of starting drug B. Rhabdomyolysis C. Erythema nodosum D. Fixed drug eruption

ANSWER: D. Fixed drug eruption. Azathioprine hypersensitivity syndrome features include: fever, cardiovascular collapse, maculopapular rash, vesiculopustular eruptions, purpura, erythema multiforme, urticaria, angioedema, erythema nodosum, GI symptoms, pancreatitis, hepatotoxicity, arthralgia, myalgia, rhabdomyolysis, renal insufficiency, pneumonitis. Fixed drug eruption is NOT a classic feature.

QUESTION 6: A patient on azathioprine for chronic actinic dermatitis also takes warfarin for atrial fibrillation. What change in warfarin management is expected? A. Warfarin dose should be reduced by 50% B. Warfarin dose may need significant increase C. No change required D. Switch to NOAC as azathioprine causes severe warfarin potentiation

ANSWER: B. Azathioprine paradoxically DECREASES the anticoagulant effect of warfarin. The patient may need a significantly higher warfarin dose. Monitor INR closely when starting or stopping azathioprine.

QUESTION 7: The earliest sign of azathioprine-induced bone marrow toxicity is most commonly: A. Anemia B. Neutropenia C. Thrombocytopenia D. Pancytopenia

ANSWER: C. Thrombocytopenia. This is often the earliest hematologic indicator of bone marrow toxicity from azathioprine, as platelets reflect early megakaryocyte suppression.

QUESTION 8: Patients with which genetic condition experience NO immunosuppressive effect from azathioprine? A. Glucose-6-phosphate dehydrogenase deficiency B. Lesch-Nyhan syndrome C. Crigler-Najjar syndrome D. Gaucher disease

ANSWER: B. Lesch-Nyhan syndrome (HGPRT deficiency). HGPRT is the enzyme required to convert 6-MP into the active immunosuppressive metabolite 6-TG. Without HGPRT, no active metabolites are produced, and azathioprine has no clinical effect.

QUESTION 9: What is the recommended monitoring frequency for CBC and LFTs after the first 2 months of azathioprine therapy? A. Monthly B. Every 2-3 months C. Every 6 months D. Annually

ANSWER: B. Every 2-3 months. In the first 2 months, monitoring is biweekly. After that, it transitions to every 2-3 months for the duration of treatment.

QUESTION 10: Which of the following diseases showed efficacy for azathioprine in a placebo-controlled double-blind trial with early termination due to rapid statistical significance? A. Pemphigus vulgaris B. Chronic actinic dermatitis C. Bullous pemphigoid D. Atopic dermatitis

ANSWER: B. Chronic actinic dermatitis. The RCT demonstrated that azathioprine was successful and well-tolerated, with statistical significance reached so rapidly that the trial was terminated early. In another study, improvement appeared permanent after a mean duration of 11.5 months.

QUESTION 11: Which statement about TPMT testing is TRUE? A. Genotype testing is preferred over phenotype testing B. TPMT activity is fixed and does not change over time C. TPMT is inducible and its activity is not constant D. TPMT testing should be repeated every 6 months

ANSWER: C. TPMT is inducible and not a constant. Its activity range can vary. This is one reason phenotypic testing (measuring actual enzyme activity) is preferred over genotype testing. After baseline phenotyping, TPMT testing does NOT need to be repeated.

QUESTION 12: Which drug class inhibits TPMT activity and can potentiate azathioprine toxicity? A. ACE inhibitors B. Aminosalicylates (sulfasalazine, mesalamine) C. Beta-blockers D. Proton pump inhibitors

ANSWER: B. Aminosalicylates (sulfasalazine, mesalamine) inhibit TPMT enzyme activity, effectively reducing the catabolic pathway for 6-MP, shunting more into the anabolic pathway, increasing 6-TG accumulation and risk of myelosuppression.

QUESTION 13: A patient with Behcet's disease on azathioprine in a randomized controlled trial showed improvement in: A. Cutaneous lesions only B. Ocular abnormalities, oral/genital ulcers, and arthritis C. Arthritis only D. Oral ulcers only

ANSWER: B. Two placebo-controlled double-blind trials of azathioprine in Behcet's disease showed decreased ocular abnormalities (including hypopyon and emergent blindness), fewer oral and genital ulcers, and decreased arthritis.

QUESTION 14: What is the maximum dose of azathioprine for a patient with NORMAL TPMT activity? A. 1.0 mg/kg/day B. 1.5 mg/kg/day C. 2.0-2.5 mg/kg/day D. 3.0 mg/kg/day

ANSWER: C. 2.0-2.5 mg/kg/day for normal TPMT activity (greater than 15.1 U/mL).

QUESTION 15: The half-life of azathioprine is approximately: A. 1-2 hours B. 5 hours C. 12 hours D. 24 hours

ANSWER: B. 5 hours. However, the active metabolite 6-TG has a much longer tissue half-life, which is why clinical effects persist and why the drug takes 8-12 weeks for maximum effect.

Sources for this complete note:

PRIMARY SOURCE: Badalamenti SS, Kerdel FA. Azathioprine. In: Wolverton SE (ed). Comprehensive Dermatologic Drug Therapy, 3rd Edition. Chapter 14, pp. 182-189.

FITZPATRICK: Dermatology (8th Edition), Wolff K, Goldsmith LA et al. (eds). Chapter 190: Immunosuppressive/Antiinflammatory Agents. Fitzpatrick's Dermatology Editors Volume 1, 2 (9780071837781), Block 30.

BOLOGNA: Dermatology 2-Volume Set, 5th Edition, Bolonia JL, Schaffer JV, Cerroni L (eds). Chapter 130: Systemic Immunomodulators. (9780702082252), Block 29, pp. 2756+.

ANDREWS: Andrews' Diseases of the Skin E-Book, Clinical Dermatology (9780323547536), Block 6.

GOODMAN & GILMAN: The Pharmacological Basis of Therapeutics, 14th Edition. Chapter on Azathioprine (9781264258079), Block 11.

PUBMED RECENT EVIDENCE:

Chu AWL et al. Systemic treatments for atopic dermatitis. J Allergy Clin Immunol 2023 Dec. PMID: 37678577
Drucker AM et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis. JAMA Dermatol 2024 Sep. PMID: 39018058
Davis DMR et al. AAD Guidelines for atopic dermatitis management. JAAD 2024 Feb. PMID: 37943240
Firestein & Kelley's Textbook of Rheumatology, 2-Volume Set (9780323935364), Block 14.

This is a shared conversation. Sign in to Orris to start your own chat.